Experiences on Conversion to Once-Daily Advagraf and Sirolimus Combination in Stable Kidney Recipients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jun, H. | - |
dc.contributor.author | Jung, C. -W. | - |
dc.contributor.author | Kim, M. -G. | - |
dc.contributor.author | Park, K. -T. | - |
dc.date.accessioned | 2021-09-05T10:58:45Z | - |
dc.date.available | 2021-09-05T10:58:45Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-03 | - |
dc.identifier.issn | 0041-1345 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/99128 | - |
dc.description.abstract | In transplant recipients, nephrotoxicity due to long-term use of calcineurin inhibitor (CM) is a serious problem that cannot be overlooked. Medication compliance can cause graft failure in transplant recipients who are bound to long-term medication. In this study, 36 patients who underwent conversion to once-daily Advagraft and sirolimus combination at Korea University Anam Hospital from September 2011 to March 2013 were retrospectively reviewed at 3 and 6 months for laboratory findings, mean arterial pressure (MAP), and so on. After conversion, serum creatinine level and glomerular filtration rate (GFR) decreased significantly at 3 months (P = .024 and P < .001, respectively). Fasting serum glucose level and proteinuria increased significantly at 6 months (P = .016 and P = .030, respectively). The impact of time after conversion at 3 months was significantly related to the increase in postoperative estimated glomerular filtration rate (eGFR). Graft rejection, morbidity, and mortality did not occur within the study period. A once-daily Advagraf and sirolimus regimen can be a novel standard regimen in stable kidney recipients due to its effects in improving renal function and convenience for patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.subject | LIVER-TRANSPLANT RECIPIENTS | - |
dc.subject | RENAL-TRANSPLANTATION | - |
dc.subject | ADHERENCE | - |
dc.subject | SURVIVAL | - |
dc.subject | EXPOSURE | - |
dc.subject | SAFETY | - |
dc.subject | TRIAL | - |
dc.subject | GRAFT | - |
dc.title | Experiences on Conversion to Once-Daily Advagraf and Sirolimus Combination in Stable Kidney Recipients | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, C. -W. | - |
dc.contributor.affiliatedAuthor | Kim, M. -G. | - |
dc.identifier.doi | 10.1016/j.transproceed.2014.01.004 | - |
dc.identifier.wosid | 000333572100025 | - |
dc.identifier.bibliographicCitation | TRANSPLANTATION PROCEEDINGS, v.46, no.2, pp.400 - 402 | - |
dc.relation.isPartOf | TRANSPLANTATION PROCEEDINGS | - |
dc.citation.title | TRANSPLANTATION PROCEEDINGS | - |
dc.citation.volume | 46 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 400 | - |
dc.citation.endPage | 402 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalResearchArea | Transplantation | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.relation.journalWebOfScienceCategory | Transplantation | - |
dc.subject.keywordPlus | LIVER-TRANSPLANT RECIPIENTS | - |
dc.subject.keywordPlus | RENAL-TRANSPLANTATION | - |
dc.subject.keywordPlus | ADHERENCE | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | EXPOSURE | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | GRAFT | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.